🔍

SUDEEPPHRM - Sudeep Pharma

📊 NSE: SUDEEPPHRM 🏢 Pharmaceuticals 📅 Last Updated: 11/13/2025 15:25

📢 Recent Corporate Announcements

Sudeep Pharma Q3 FY26 Earnings Call: 20% Domestic Growth and Major Capacity Expansion

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 12 Feb 2026, 11:09 AM

Sudeep Pharma reported a steady Q3 FY26 performance with 20% growth in the domestic market and strong traction in APAC and Europe. The company is strategically pivoting towards high-margin specialty ingredients and battery-grade iron phosphate, positioning itself as a key ex-China supplier. Significant capacity expansions are underway, including the 51,200 MTPA Nandesari facility due in March 2026 and the 25,000 MTPA Dahej battery materials plant slated for 2027. Management highlighted deepening relationships with global FMCG and baked goods leaders, providing long-term revenue visibility.

Domestic market revenue grew by nearly 20% in Q3 FY26 supported by stable demand.
Nandesari Greenfield facility with 51,200 MTPA capacity is on track for commissioning in March 2026.
Phase 1 of the Dahej Battery Materials facility (25,000 MTPA) is scheduled for commissioning in early 2027.
Currently engaged with 34 global customers for battery-grade iron phosphate, with a 70% sample approval rate.
Upgraded existing facilities to add 5,000 tons of battery-grade iron phosphate capacity to serve commercial scale-up orders.

💡 Investors should monitor the timely commissioning of the Nandesari facility in March 2026 as it will drive the next phase of volume growth. The company's unique position as an ex-China supplier for battery materials makes it a high-potential play in the EV supply chain.

Sudeep Pharma Releases Audio Recording of Q3 FY26 Earnings Call

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 09 Feb 2026, 02:15 PM

Sudeep Pharma Limited has informed the exchanges that the audio recording of its Q3 FY26 earnings conference call, held on February 9, 2026, is now available for public access. This filing is a procedural requirement under Regulation 30 of the SEBI Listing Regulations. The recording allows investors to hear management's detailed commentary on the company's quarterly performance and strategic outlook. A written transcript of the session is expected to be submitted to the exchanges separately in the near future.

Earnings call for the third quarter of FY26 was successfully conducted on February 9, 2026.
Audio recording link has been hosted on the official company website for investor transparency.
The filing follows previous intimations regarding the earnings call and investor presentation dated February 2 and 7, 2026.
A formal written transcript of the call will be filed with the stock exchanges as a separate disclosure.

💡 Investors should listen to the recording to gain deeper insights into management's qualitative commentary on Q3 results. No immediate action is required as this is a routine regulatory disclosure.

Sudeep Pharma Q3 FY26 PAT Surges 66% YoY; Groundbreaking for 25,000 MT Battery Chemicals Plant

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 07 Feb 2026, 03:28 PM

Sudeep Pharma reported a robust Q3 FY26 with total income rising 52% YoY to ₹179.2 crore, driven by strong demand in specialty ingredients and pharma segments. Profit After Tax (PAT) surged 66% YoY to ₹47.7 crore, supported by healthy EBITDA margins of 37.3%. A major strategic highlight is the company's entry into the EV battery materials space with a new 25,000 MT plant in Dahej and the commencement of early commercial orders. The company is also on track to commission its Nandesari greenfield facility by Q4 FY26, further boosting capacity.

Total Income grew 52% YoY to ₹179.2 Cr in Q3 FY26; 9M FY26 revenue reached ₹482.1 Cr.
EBITDA increased 60% YoY to ₹66.8 Cr with margins expanding to 37.3% from 35.4% YoY.
Groundbreaking of Dahej Battery Chemicals Plant (Phase I: 25,000 MT) targeting the LFP battery market with a total project cost of ₹300 Cr.
Successfully upgraded existing iron phosphate capacity to 5,000 MT for battery-grade materials and secured initial commercial orders.
Greenfield manufacturing facility at Nandesari is on track for commissioning by Q4 FY26.

💡 Investors should note the strong earnings momentum and the significant strategic pivot into the high-growth EV battery materials sector as a long-term catalyst. Monitor the execution timelines of the Dahej plant and the ramp-up of the new Nandesari facility for sustained growth.

Sudeep Pharma Re-schedules Q3 FY26 Earnings Call to February 9, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 07 Feb 2026, 12:31 PM

Sudeep Pharma Limited has re-scheduled its earnings conference call to discuss the financial performance for the quarter and nine months ended December 31, 2025. The call is now set for Monday, February 9, 2026, at 11:00 a.m. IST, moving from its previously planned schedule. Senior management, including the Managing Director and CFO, will be present to discuss business strategy and the outlook post-Q3 results. This update follows an initial intimation made by the company on February 2, 2026.

Earnings call re-scheduled for February 9, 2026, at 11:00 a.m. IST
Focus on operational and financial performance for Q3 and nine months ended Dec 31, 2025
Management participants include MD Sujit Bhayani and CFO Ketan Vyas
International access provided for investors in USA, UK, Singapore, and Hong Kong

💡 Investors interested in the company's Q3 performance should update their calendars for the new call time to hear management's commentary on growth. No fundamental change in company value is implied by this administrative scheduling update.

Sudeep Pharma Q3 FY26 Net Profit Rises 30% YoY to ₹26.87 Crore; Revenue Up 8%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 06 Feb 2026, 06:12 PM

Sudeep Pharma reported a strong performance for Q3 FY26, with standalone net profit growing 30.2% year-on-year to ₹26.87 crore. Revenue from operations saw a steady increase of 8.1% to ₹90.28 crore, while total income was bolstered by a significant rise in other income to ₹9.44 crore. For the nine-month period ended December 2025, the company achieved a profit of ₹81.82 crore, a 30.7% increase compared to the previous year. The company, which listed in November 2025, still holds ₹75.81 crore of unutilized IPO proceeds in term deposits intended for future capital expenditure.

Net Profit for Q3 FY26 increased by 30.2% YoY to ₹26.87 crore from ₹20.63 crore.
Revenue from operations grew 8.1% YoY to ₹90.28 crore in the December quarter.
9M FY26 profit stands at ₹81.82 crore, up significantly from ₹62.61 crore in 9M FY25.
Other income jumped to ₹9.44 crore in Q3 FY26 compared to ₹2.29 crore in the same quarter last year.
Unutilized IPO proceeds of ₹75.81 crore are currently held in bank term deposits for planned machinery procurement.

💡 The company shows robust profit growth and efficient cost management in its first results post-listing. Investors should monitor the timely deployment of IPO proceeds into machinery, which is the primary catalyst for future capacity expansion.

Sudeep Pharma Q3 PAT Jumps 30% YoY to ₹26.87 Cr; Revenue Up 8.1%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 06 Feb 2026, 06:03 PM

Sudeep Pharma Limited reported a strong performance for the quarter ended December 31, 2025, with Profit After Tax (PAT) rising 30.2% YoY to ₹26.87 crore. Revenue from operations grew by 8.1% YoY to ₹90.28 crore, while 9-month PAT reached ₹81.82 crore compared to ₹62.61 crore in the previous year. The company, which listed in November 2025, still holds ₹75.81 crore of its IPO proceeds in term deposits pending deployment for capital expenditure. Additionally, the board has appointed Sharp & Tannan Associate as the internal auditor for FY 2026-27.

Net Profit increased by 30.2% YoY to ₹26.87 crore in Q3 FY26 from ₹20.63 crore in Q3 FY25.
Revenue from operations grew 8.1% YoY to ₹90.28 crore against ₹83.48 crore in the previous year's quarter.
9-month PAT stands at ₹81.82 crore, showing significant growth over the ₹62.61 crore reported for the same period last year.
Unutilized IPO proceeds of ₹75.81 crore are currently held in bank term deposits for future machinery procurement.
Earnings Per Share (EPS) for the quarter improved to ₹2.42 from ₹1.90 YoY.

💡 Investors should monitor the timely deployment of the remaining ₹75.81 crore IPO proceeds into production machinery, which will be the primary driver for future capacity expansion. The strong bottom-line growth post-listing is a positive signal for long-term holders.

Sudeep Pharma USA VP Sales & Supply Chain John Garcia Resigns Effective Feb 6, 2026

🔵 WATCH ⭐ 4/10

MANAGEMENT 📅 05 Feb 2026, 10:12 AM

Mr. John Garcia, the Vice President of Sales & Supply Chain at Sudeep Pharma USA Inc, a wholly-owned subsidiary of Sudeep Pharma Limited, has resigned from his position. Classified as Senior Management Personnel (SMP), his resignation is effective from the close of business hours on February 6, 2026. The departure is attributed to his desire to pursue new professional challenges and opportunities outside the group. This transition impacts the leadership of the company's international sales and supply chain operations in the US market.

Mr. John Garcia resigned as Vice President - Sales & Supply Chain of Sudeep Pharma USA Inc.
The resignation becomes effective from the close of business hours on February 6, 2026.
The individual was officially designated as Senior Management Personnel (SMP) per SEBI guidelines.
The reason for departure is to pursue new challenges and opportunities elsewhere.

💡 Investors should monitor the company's announcement regarding a successor to ensure continuity in US sales operations. While management turnover in subsidiaries is common, any impact on US revenue growth should be observed in upcoming quarterly results.

Sudeep Pharma to Host Q3FY26 Earnings Call on February 9, 2026

🟡 NEUTRAL ⭐ 4/10

EARNINGS 📅 02 Feb 2026, 04:52 PM

Sudeep Pharma Limited has scheduled an earnings conference call for Monday, February 9, 2026, at 11:30 AM IST to discuss its Q3FY26 financial results. The management team, including the Managing Director and CFO, will provide insights into the operational performance for the nine months ended December 31, 2025. This call, organized by IIFL, will also cover the company's future business strategy and outlook. Investors can access the call through universal dial-in numbers or international toll-free lines.

Earnings call scheduled for February 9, 2026, at 11:30 AM IST
Discussion to focus on Q3 and nine-month performance ending December 31, 2025
Management participants include MD Sujit Bhayani, Director Shanil Bhayani, and CFO Ketan Vyas
Universal access numbers for the call are +91 22 6280 1259 and +91 22 7115 8160

💡 Investors should attend or review the transcript of the call to understand management's guidance on growth and margin trends. Pay close attention to any updates regarding business strategy and sector-specific outlook.

Sudeep Pharma Subsidiary Acquires Land in Dahej for ₹20.97 Cr for Battery Materials Plant

🟢 POSITIVE ⭐ 7/10

EXPANSION 📅 22 Jan 2026, 05:16 PM

Sudeep Pharma's wholly-owned subsidiary, Sudeep Advanced Materials Private Limited, has acquired leasehold land rights in GIDC Dahej, Gujarat, for ₹20.97 crore. The land, measuring approximately 80,980 square meters, was purchased from DCM Shriram Fine Chemicals Limited. This strategic acquisition is intended for setting up a commercial manufacturing facility for Battery Grade Precursor Materials, specifically Iron Phosphate. This move marks a significant expansion into the high-growth electric vehicle and energy storage supply chain.

Acquisition of 80,980.19 square meters of leasehold land in GIDC Dahej, Gujarat
Total transaction value of ₹20,97,03,000 excluding transfer charges and duties
Land purchased from DCM Shriram Fine Chemicals Limited by a wholly-owned subsidiary
New facility to focus on manufacturing Battery Grade Precursor Materials like Iron Phosphate
Strategic diversification into the renewable energy and EV battery material sector

💡 Investors should view this as a positive long-term growth driver as the company enters the specialized battery materials market. Monitor future announcements regarding project timelines, capital expenditure for the plant, and potential off-take agreements.

Sudeep Pharma Updates CIN and Status to 'Listed' on MCA Portal

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 16 Jan 2026, 11:15 AM

Sudeep Pharma Limited has successfully updated its Corporate Identification Number (CIN) and status on the Ministry of Corporate Affairs (MCA) website following its listing on the BSE and NSE on November 28, 2025. The CIN has officially changed from 'U' (Unlisted) to 'L' (Listed) to reflect its public status. The company's paid-up capital is recorded at Rs 11.29 crore against an authorized capital of Rs 15 crore. This is a standard administrative procedure required for all newly listed entities in India.

CIN changed from U24231GJ1989PLC013141 to L24231GJ1989PLC013141
Company status officially updated from 'Unlisted' to 'Listed' on MCA records
Paid-up capital stands at Rs 11,29,48,625 as of January 16, 2026
Authorized capital for the company is Rs 15,00,00,000
Listing on BSE and NSE was completed on November 28, 2025

💡 No action is required as this is a routine administrative update following the company's initial public offering and subsequent listing.

Sudeep Pharma Submits SEBI Regulation 74(5) Compliance Certificate for Q3 FY2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 08 Jan 2026, 03:21 PM

Sudeep Pharma Limited has submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2025. The company's Registrar and Share Transfer Agent, MUFG Intime India Private Limited, confirmed that no dematerialization requests were received during this period. This is attributed to the fact that 100% of the company's shares are already held in electronic mode. This filing is a standard administrative requirement for listed entities in India.

Compliance certificate filed for the quarter ended December 31, 2025
Registrar MUFG Intime India confirmed zero demat requests were processed during the quarter
Company confirms all shares are currently held in electronic mode only
Filing adheres to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018

💡 No action is required from investors as this is a routine regulatory filing. Investors should continue to monitor the company's upcoming quarterly financial performance.

Sudeep Pharma to Close Trading Window from Jan 1, 2026, for Q3 FY26 Results

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 26 Dec 2025, 02:36 PM

Sudeep Pharma Limited has announced the closure of its trading window for all designated persons and their immediate relatives starting January 1, 2026. This closure is a mandatory regulatory requirement under SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the declaration of financial results. The window will remain closed until 48 hours after the un-audited financial results for the quarter ending December 31, 2025, are made public. The specific date for the board meeting to approve these results will be communicated separately.

Trading window closure commences on Thursday, January 1, 2026.
Closure pertains to the un-audited financial results for the quarter ending December 31, 2025.
The window will reopen 48 hours after the official declaration of the quarterly results.
Restriction applies to all designated persons and their immediate relatives as per SEBI PIT Regulations.

💡 No action is required as this is a routine regulatory filing. Investors should look out for the upcoming announcement regarding the board meeting date for Q3 results.

Sudeep Pharma Q2 FY26: Specialty Segment Grows 32% CAGR; New Plant to Commission in Q4

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 25 Dec 2025, 04:55 PM

Sudeep Pharma conducted its maiden earnings call post-listing, highlighting a robust 32% CAGR in its specialty ingredients vertical since 2021, which now accounts for 40% of total revenue. The company is on track to commission its fifth and largest manufacturing facility in Nandesari by Q4 FY26 to address rising demand in regulated pharma and infant nutrition markets. Management clarified that 50% of its US business is exempt from recent tariffs, with customers absorbing the remaining impact, ensuring no significant volume loss. The strategic 85% acquisition of Ireland-based NSS in May 2025 further strengthens its global footprint in the high-barrier infant and medical nutrition segments.

Specialty ingredients vertical achieved a 32% CAGR since 2021, contributing 40% of H1 FY26 revenues.
Fifth greenfield manufacturing facility in Nandesari, Gujarat, expected to be commissioned in Q4 FY26.
Acquired 85% stake in Ireland-based Nutrition Supplies and Services (NSS) to accelerate entry into infant nutrition.
Management confirmed 50% of US business is exempt from tariffs, with the rest seeing costs absorbed by clients.
Expanding into the battery materials market through Sudeep Advanced Materials (SAM) for LFP battery components.

💡 Investors should monitor the successful commissioning and ramp-up of the Nandesari facility in Q4 FY26 as a key growth driver. The stock offers unique exposure to high-barrier pharmaceutical excipients and the emerging LFP battery material supply chain.

Sudeep Pharma Releases Audio Recording of December 2025 Earnings Call

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 22 Dec 2025, 04:28 PM

Sudeep Pharma Limited has officially released the audio recording of its earnings conference call conducted on December 22, 2025. This disclosure is in compliance with Regulation 30 of the SEBI Listing Regulations, 2015, following the company's investor presentation released on December 21, 2025. The recording is accessible via the company's website, providing transparency regarding management's discussion on financial performance. A formal written transcript of the proceedings is expected to be filed separately.

Earnings call successfully conducted on December 22, 2025
Audio recording made available via official company website link
Compliance with SEBI Listing Regulations Regulation 30
Written transcript of the call to be submitted in a separate filing

💡 Investors should listen to the audio recording or wait for the transcript to gain insights into management's future guidance and operational performance. No immediate trading action is required based solely on this procedural filing.

Sudeep Pharma Q2FY26 Update: FY25 Revenue at ₹502 Cr with 39.7% EBITDA Margin

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 21 Dec 2025, 04:29 PM

Sudeep Pharma, which listed on BSE/NSE in November 2025, reported robust FY25 financials with a PAT of ₹139 crore and a high ROE of 28.1%. The company is undergoing a major capacity expansion, adding 51,200 MT to its existing 72,246 MT capacity, with commissioning expected by Q4FY26. It maintains a strong global presence across 100 countries, serving 1,100+ customers including 14 Fortune 500 companies. Additionally, the company is diversifying into high-growth battery materials, specifically iron phosphate for LFP batteries.

FY25 Revenue of ₹502 Cr with a strong EBITDA margin of 39.7% and PAT margin of 27.6%.
Total manufacturing capacity to reach 1,23,446 MT following the commissioning of a new facility in Q4FY26.
High customer stickiness with 83.17% repeat business and an average 7-year relationship with top 5 customers.
Diversified revenue stream with 60% from Specialty Ingredients and 40% from Pharma, Food & Nutrition in H1FY26.
Strategic entry into sustainable battery materials through subsidiary Sudeep Advanced Materials (SAMPL).

💡 Investors should track the timely commissioning of the new Nandesari facility in Q4FY26, which will increase capacity by approximately 70%. The company's entry into the EV battery material supply chain provides a significant long-term growth catalyst beyond its core pharma excipients business.

View All SUDEEPPHRM Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

In H1 FY26, the Specialty business contributed 60% of revenue (growing significantly with the NSS acquisition), while the Pharma, Food, and Nutrition segment contributed 40%. In Q2 FY26, the Pharma, Food, and Nutrition business saw a 7% YoY decline, while Specialty ingredients grew 2% when excluding the INR 20 Cr contribution from NSS.

Geographic Revenue Split

International business (including exports) contributed 61% of total revenue in H1 FY26, while domestic sales accounted for 39%. The U.S. remains the company's largest regulated market.

Profitability Margins

Gross margins have returned to a historical average of 63%-64% in FY26 after an exceptional FY25 where raw material price drops were not immediately passed to customers. PAT margin stood at 27.1% in Q2 FY26 compared to 32.4% in Q2 FY25.

EBITDA Margin

EBITDA margin for Q2 FY26 was 38.0%, a decrease from 43.4% in Q2 FY25. H1 FY26 EBITDA margin was 37.9% compared to 40.9% in H1 FY25, reflecting upfront investments in global sales teams and warehousing.

Capital Expenditure

The company has a Greenfield project outlay of INR 150 Cr for a 51,200 MT facility. As of September 2025, INR 120 Cr has been spent, with the remaining INR 20-30 Cr expected to be incurred by March 2026 via internal accruals.

Credit Rating & Borrowing

Not disclosed in available documents; however, the company maintains a conservative leverage position with a Net Debt to Equity ratio of 0.1x and net debt of INR 73 Cr as of September 30, 2025.

⚙️ Operational Drivers

Raw Materials

Mineral-based chemistries and vitamins (specific minerals like calcium are implied by the excipient portfolio). Raw materials consumed accounted for INR 164.8 Cr in FY25, representing approximately 32.8% of total revenue.

Import Sources

Not explicitly disclosed, though the company operates globally and manages international supply chains to service 100 countries.

Capacity Expansion

Current manufacturing capacity is 72,246 MT across 4 facilities. A Greenfield expansion in Dahej will add 51,200 MT, bringing total capacity to 123,446 MT. Additionally, a battery material facility with 25,000 MT capacity is targeted for early 2027.

Raw Material Costs

Cost of materials consumed was INR 103.3 Cr in H1 FY26, up 54% from INR 67.1 Cr in H1 FY25, primarily due to the NSS acquisition and business mix changes.

Manufacturing Efficiency

Overall capacity utilization is approximately 50%. The Pharma, Food, and Nutrition vertical operates at ~65% utilization, nearing its optimum level of 70%, which triggered the current Greenfield expansion.

Logistics & Distribution

Other expenses (including distribution and global sales team costs) rose to INR 58.7 Cr in H1 FY26 from INR 52.2 Cr in H1 FY25, representing 20.4% of H1 revenue.

📈 Strategic Growth

Expected Growth Rate

26%

Growth Strategy

Growth will be driven by the integration of the NSS acquisition (Ireland), which provides immediate access to the infant nutrition market, and the expansion into battery materials with a 25,000 MT facility. The company is also shifting to a direct sales model in the US and Europe to capture 15-20% additional margin previously held by distributors.

Products & Services

Mineral-based pharmaceutical excipients, specialty ingredients for infant and clinical nutrition, and advanced materials for batteries.

Brand Portfolio

Sudeep Pharma, Nutrition Supplies and Services (NSS).

New Products/Services

Entry into the high-growth battery material segment with a dedicated facility in Dahej, Gujarat, expected to contribute to revenue by FY27.

Market Expansion

Expansion into Europe via the 85% stake acquisition of NSS in May 2025 and strengthening presence in Latin America with localized stocking.

Market Share & Ranking

Sudeep is the only Indian company approved to supply the three largest global infant nutrition companies, a process that typically takes 5-7 years.

Strategic Alliances

Acquired 85% stake in Nutrition Supplies and Services (NSS), Ireland, to bypass the 4-5 year regulatory approval timeline for infant nutrition.

🌍 External Factors

Industry Trends

The industry is seeing a 'China Plus One' shift; Sudeep is positioning itself as one of the first scalable suppliers of specialty ingredients outside of China.

Competitive Landscape

Limited competition in India and China for its specific technology-led functional ingredients due to high regulatory and customer approval hurdles.

Competitive Moat

High barriers to entry due to a 5-7 year customer approval cycle in infant nutrition and complex regulatory requirements. Sudeep's status as the only Indian supplier to the top 3 global infant nutrition firms provides a durable competitive advantage.

Macro Economic Sensitivity

Sensitive to global economic growth and interest rates, as 61% of revenue is international.

Consumer Behavior

Increased demand for clinical and infant nutrition is driving the focus on the Specialty Ingredients vertical.

Geopolitical Risks

Exposure to international trade regulations and potential tariff impacts, particularly in the U.S. market.

⚖️ Regulatory & Governance

Industry Regulations

Operations are subject to stringent product-specific regulatory approvals in the US and Europe; the company currently holds 10 such approvals.

Taxation Policy Impact

Effective tax rate was approximately 24.2% in FY25 (INR 44.2 Cr tax on INR 182.8 Cr PBT).

⚠️ Risk Analysis

Key Uncertainties

Integration risks associated with the NSS acquisition and the successful commercialization of the new battery materials segment by 2027.

Geographic Concentration Risk

61% of revenue is derived from international markets, with the U.S. being the largest single market, creating high sensitivity to U.S. trade policies.